University of Bern, Switzerland - Decrease in mortality from rare side effect [A large-scale international study co-led by Inselspital and the University of Bern]

Title:

Decrease in mortality from rare side effect

 

Published:

University of Bern, 28 September 2021

Click here to read

 

From the media release:

A large-scale international study co-led by Inselspital and the University of Bern investigated the very rare adverse cerebral venous occlusion (sinus venous thrombosis) after administration of the Oxford-AstraZeneca and Janssen/Johnson&Johnson vaccines. Neither vaccine has been used in Switzerland to date. The mortality rate due to this complication decreased from 61% to 42% after the mechanism of its onset was clarified in spring 2021.